

IMPORTANT: Investment involves risks. Investment value may rise or fall. Past performance information presented is not indicative of future performance. Investors should refer to the Prospectus and the Product Key Facts Statement for further details, including product features and the full list of risk factors. Investors should not base on this document alone to make investment decisions.

CSOP Nikkei 225 Daily (2x) Leveraged Product (the "Product") is a sub-fund of CSOP Leveraged and Inverse Series, an umbrella unit trust established under Hong Kong law. Units of the Product (the "Units") are traded in HKD on The Stock Exchange of Hong Kong Limited (the "SEHK") like stocks. It is a futures-based product which invests directly in the nearest quarter futures contracts on the Index traded on the Osaka Exchange, Inc. (the "OSE") in Japan ("Nikkei 225 Futures") (and/or nearest quarter Nikkei 225 mini futures traded on the OSE ("Nikkei 225 mini")), so as to provide Daily investment results which, before fees and expenses, closely correspond to twice (2x) the Daily performance of the Index. It is denominated in JPY. Creations and redemptions are in USD or JPY. **CSOP Nikkei 225 Daily (-2x) Inverse Product** (the "Product") is a sub-fund of CSOP Leveraged and Inverse Series, an umbrella unit trust established under Hong Kong law. Units of the Product (the "Units") are traded in HKD on The Stock Exchange of Hong Kong Limited (the "SEHK") like stocks. It is a futures-based product which invests directly in the nearest quarter futures contracts on the Index traded on the Osaka Exchange, Inc. (the "OSE") in Japan ("Nikkei 225 Futures") (and/or nearest quarter Nikkei 225 mini futures traded on the OSE ("Nikkei 225 mini")), so as to provide Daily investment results which, before fees and expenses, closely correspond to two times inverse (-2x) of the Daily performance of the Index. It is denominated in JPY. Creations and redemptions are in USD or JPY. The Products are not intended for holding longer than one day. The Products are subject to concentration risks as a result of tracking the leveraged or two times inverse performance of the Index which focuses on a single country (i.e. Japan). The OSE has the right to suspend trading in any security traded thereon. The Japanese government or the regulators in Japan may also implement policies that may affect the Japanese financial market. All of these may have a negative impact on the Product. The Product's base currency is JPY and the underlying investments of the Product are primarily denominated in JPY. Payment of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor's original investment or from any capital gains attributable to that original investment and may result in an immediate reduction of the NAV per Unit. The OSE and the SEHK have different trading hours. Please note that the above listed investment risks are not exhaustive, and investors should read the Prospectus and the Product Key Facts for further details (including product features and the full list risk factors) before making any investment decision.

Seizing Japan's market potential.
Capturing Nikkei's ups & downs.

7262



7515

**CSOP Nikkei 225
Daily (2x) Leveraged
Product (7262.HK)**

**CSOP Nikkei 225
Daily (-2x) Inverse
Product (7515.HK)**



INVESTMENT MADE EASY



Disclaimer

CSOP Nikkei 225 Daily (2x) Leveraged Product and CSOP Nikkei 225 Daily (-2x) Inverse Product are authorized by the Securities and Futures Commission ("SFC") in Hong Kong. Such authorization does not imply any official recommendation by the SFC. This document and the information contained in it are for general information only and do not constitute financial, professional, investment or any other kind of advice in any way. This document should not be regarded as an offer or solicitation of business, nor should it be construed as an offer, solicitation, invitation, or recommendation to buy or sell any securities, funds, or other investment products or enter into any transaction in any jurisdiction to any person or entity to whom it is unlawful to make such an invitation, offer, solicitation, or recommendation in such jurisdictions. Investors should not base on this document alone to make investment decisions. Investors should understand the nature and risks of the relevant investment products and make investment decisions based on their own financial situation, investment objectives and experiences, willingness and ability to bear risks and specific needs; and if necessary, should seek independent professional advice before making any investment decisions. CSOP Asset Management Limited ("CSOP") which prepared this document believes that information in this document is based upon sources that are believed to be accurate, complete, and reliable. However, CSOP does not warrant the accuracy, reliability, timeliness, completeness or reasonableness and CSOP shall not be liable for any loss, damage or expense incurred directly or indirectly as a result of the use of and/or reliance upon the whole or any part of the information in this document. This document is not directed to, intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution, availability or use would be contrary to local law or regulations, or which would subject CSOP to any registration or licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction. This document is not applicable in jurisdictions where the distribution of this material is restricted. The product is only available in jurisdictions where it can be lawfully provided. For the Index Provider Disclaimer, please refer to the Product's offering document. This document is prepared by CSOP and has not been reviewed by the SFC.

Issuer: CSOP Asset Management Limited

The linked website has not been reviewed by the SFC and may contain information of funds not authorized by the SFC.

CSOP Nikkei 225 Leveraged and Inverse Products

Uncertainties Bring Active Trading of Leveraged and Inverse Products

- Nikkei 225 index exceeded the bubble-era high seen in December 1989 in March 2024*, and market participants are holding mixed views for the outlook of Japanese equities.
- Amid the uncertainties, Nikkei 225 Leveraged and inverse products (L&Is) have been the good trading tools to capture up and down of Nikkei 225 index.



What's next after record high?

Positive Views	Negative Views
Increases in corporate targets for ROE, shareholder returns	F3/25 guidance calls for profit decline
Monetary policy remains accommodative	Japan lost crown as world's third-largest economy and economic figures disappointed.
Both sales and profits were seen expansion	Weak Yen deters foreigners from Japanese stocks

Source: Sell-side reports, as of 2024/5/22, compiled by CSOP.

Leveraged and inverse products of Nikkei 225 are the most actively traded ETPs in Japan

Among Top 10 actively traded ETPs in Japan:*




6 Nikkei 225 L&Is



4 ETFs

In Japan, the Average Daily Turnover of Nikkei 225 L&I is **10x** ADT of Nikkei 225 ETFs (Billion JPY)



Source: *Bloomberg, 2024/1/4-2024/5/10.

CSOP Nikkei 225 L&I Pair to Gain Flexibility for Long & Short

CSOP Nikkei 225 Daily **(2x) Leveraged Product**

CSOP Nikkei 225 Daily **(-2x) Inverse Product**

The World's (ex Japan) **1st Nikkei 225 Index Leveraged and Inverse Products**



	7262	7515
Stock Code	7262	7515
Short Name	FL2 CSOP NIKKEI	FI2 CSOP NIKKEI
Investment Objective	To provide investment results that, before fees and expenses, closely correspond to twice (2x) the Daily performance of the Index. The Product does not seek to achieve its stated investment objective over a period of time greater than one day.	To provide investment results that, before fees and expenses, closely correspond to two times inverse (-2x) of the Daily performance of the Index. The Product does not seek to achieve its stated investment objective over a period of time greater than one day.
Listing Date	29 May 2024	
Exchange	Hong Kong Stock Exchange – Main Board	
Index	Nikkei Stock Average	
Fund Manager	CSOP Asset Management Limited	
Investment Strategy	A futures-based replication strategy	
Base Currency	JPY	
Trading Currency	HKD	
Trading Lot Size	10 Units	
Minimum Investment [^]	100 USD (~ 780 HKD)	
Management Fee ^{^^}	1.60%	
Application Unit Size (only by or through Participating Dealers)	Minimum 50,000 Units (or multiples thereof)	
Ongoing Charges over a year [#]	1.99%	
Trustee	HSBC Institutional Trust Services (Asia) Limited	

Nikkei 225 Futures (and/or Nikkei 225 mini)

(No more than **40%** NAV)

Cash (JPY, HKD or USD) and other HKD, RMB or USD denominated investment products

(No less than **60%** NAV)


Collective Investment Scheme

(No more than **10%** NAV)

Source: CSOP. "The First" is based on Bloomberg Fund Screening, as of 2024/5/22. [^]Estimated data, for reference only. ^{^^}Please note that the management fee may be increased up to a permitted maximum amount by providing one month's prior notice to Unitholders. Please refer to the section headed "Fees and Expenses" in the Prospectus for further details of the fees and charges payable and the permitted maximum of such fees allowed, as well as other ongoing expenses that may be borne by the Product. [#]The ongoing charges figure is indicative only as the Product is newly set up. It represents the sum of the estimated ongoing expenses chargeable to the Product expressed as a percentage of the Product's net asset value ("NAV"). The actual figure may be different from this estimated figure and it may vary from year to year. The above information is for reference only, and does not constitute an investment advice of, or an offer, solicitation, or recommendation to buy or sell any securities or investment products in any country or jurisdiction. Investment involves risk.

CSOP: Leading L&I Issuer in Hong Kong

In Hong Kong leveraged & inverse products market in 2024Q1, CSOP has dominant market shares.



Versatile Tools at Hand, Flexibly Ride the Volatilities



CSOP Nikkei 225 Product Series

ETF	CSOP Nikkei 225 Index ETF
(2x) Leveraged	CSOP Nikkei 225 Daily (2x) Leveraged Product
(-2x) Inverse	CSOP Nikkei 225 Daily (-2x) Inverse Product

Source: #Bloomberg, 2024/1/1 to 2024/3/28. ##Bloomberg, 2024/3/28.

The above information is for reference only, and does not constitute an investment advice of, or an offer, solicitation, or recommendation to buy or sell any securities or investment products in any country or jurisdiction. Investment involves risk. This material has not been reviewed by the Securities and Futures Commission in Hong Kong. Issuer: CSOP Asset Management Limited